Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Italy Fines Apple €98.6 Million Over App Store Dominance 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
 - EconoTimes)
NEW YORK, Jan. 26, 2017 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Aetna Inc. (“Aetna” or the “Company”) (NYSE:AET) in the United States District Court for the District of Connecticut on behalf of persons or entities who purchased or otherwise acquired Aetna stock between August 15, 2016 through January 20, 2017, inclusive (the “Class Period”), seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.
The Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aetna and its senior executives attempted to leverage Aetna’s participation in the Public Exchanges for favorable treatment from regulators regarding the Humana acquisition; (2) Aetna threatened to limit its participation in public health insurance exchanges if the Department of Justice (“DOJ”) attempted to block the merger; (3) Aetna did not withdraw from certain public health insurance exchanges for business reasons as Defendants claimed, but to follow through on its threat of leaving the marketplace once the DOJ filed suit and to improve its litigation position; (4) Aetna withdrew from public health insurance exchanges that were profitable for Aetna; and (5) as a result of the foregoing, Defendants’ statements about Aetna’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
If you wish to serve as lead plaintiff, you must move the Court no later than March 27, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
